<DOC>
	<DOCNO>NCT02062892</DOCNO>
	<brief_summary>The investigator hypothesize switch kidney transplant patient tacrolimus/sirolimus long-term maintenance immunosuppressive drug regimen tacrolimus/everolimus , safe , lead good kidney function patient stay tacrolimus/sirolimus due low potential everolimus enhance calcineurin inhibitor toxicity and/or ability even reverse negative effect calcineurin inhibitor vascular endothelial kidney function . To test hypothesis vascular endothelial biomarkers analyze blood plasma sample kidney dysfunction biomarkers urine sample via liquid chromatography tandem mass spectrometry evaluate whether switch kidney transplant patient tacrolimus/sirolimus tacrolimus/everolimus lead well kidney endothelial function one year two year .</brief_summary>
	<brief_title>Differentiating Everolimus Versus Sirolimus Combination With Calcineurin Inhibitors Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Kidney transplant patient ≥ 3 month transplantation . De novo patient sirolimus tacrolimus well patient switch tacrolimus sirolimus eligible long receive drug combination least 2 month . Immunosuppressive drug regimen base tacrolimus sirolimus 1870 year age calculate glomerular filtration rate≥ 30 mL/min/ 1.73m2 calculate use abbreviate Modification Diet Renal Disease formula Ability willingness provide write informed consent adhere study regimen . Patients able take oral medication time randomization . Patients switch tacrolimus sirolimus due clinically relevant nephrotoxicity previous immunosuppressive drug regimen , Patients abnormal liver profile alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase , total bilirubin &gt; 3 x upper limit normal time randomization Patients severe total hypercholesterolemia ( &gt; 350 mg/dL ; &gt; 9 mmol/L ) total hypertriglyceridemia ( &gt; 500 mg/dL ; &gt; 5.6 mmol/L ) . Patients lipid lower treatment control hyperlipidemia acceptable . Patients test positive HIV , Hepatitis C Hepatitis B surface antigen . An episode acute rejection require antibody therapy one steroid sensitive episode acute rejection prior enrollment . Spot urine protein/creatinine ratio &gt; 1g/24h time randomization Multiorgan transplant Patients platelet count &lt; 50,000 Patients absolute neutrophil count &lt; 1,000 white blood cell &lt; 2,000 time enrollment Patients hemoglobin &lt; 6g/dL Patients clinically significant systemic infection require active use IV antibiotic , antivirales , antifungal . Prophylactic use antivirales acceptable . Pregnancy inability practice acceptable contraceptive measure . Patients surgical medical condition , severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus , opinion investigator might significantly alter absorption , distribution , metabolism and/or excretion study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>everolimus</keyword>
	<keyword>sirolimus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>vascular endothelial function</keyword>
	<keyword>kidney</keyword>
	<keyword>Transplantation</keyword>
	<keyword>biomarkers</keyword>
</DOC>